The promising significance of liraglutide combined with dapagliflozin or empagliflozin in the prevention of early diabetic nephropathy
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452308/
Objective: To explore the significance of liraglutide combined with dapagliflozin or empagliflozin in the prevention of early diabetic nephropathy (DN) and its effects on renal function indices. Methods: Three hundred...
Conclusions: Liraglutide combined with dapagliflozin or empagliflozin treatment can effectively reduce the levels of Tf, NGAL and TNF-α in patients with T2DM, and improve the renal function in terms of IGF-1, RBP, Hcy, BNP, UAER, UACR, L-FABP, showing high treatment safety.
-
Dr Hamid3yrInteresting article about significance of liraglutide combined with dapagliflozin or empagliflozin in the prevention of early diabetic nephropathy (DN) and its effects on renal function indices
STUDY OF EARLY RETINAL CHANGES IN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36027108/
In patients with a very recent diagnosis of Type 2 Diabetes Mellitus, the retinal vessels diameters do not differ compared with individuals of similar age and blood pressure. However, the...
Conclusions: In patients with a very recent diagnosis of Type 2 Diabetes Mellitus, the retinal vessels diameters do not differ compared with individuals of similar age and blood pressure. However, the AVR index correlates with age and nighttime BP, highlighting the important contribution of the latter in early target organ damage in this...
-
Amy Gonzales, MARK MALONE, MD, PA3yrThis reminds of what I learned in med school. Patients with type 1 DM should see their eye doctor every ~5 yrs for screening. For patient with type 2 DM, Show More
The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36135828/
doi: 10.3390/medicines9090047. 1 Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu City 879-5593, Oita, Japan. 2 Faculty of Medicine, Oita University, Yufu City 879-5593, Oita,...
Conclusions: These results suggest that the GLP1-RA semaglutide effectively reduces body adiposity while maintaining the MM in obese type 2 diabetic patients.
-
Dr Hamid3yrInteresting article that shows semaglutide effectively reduces body adiposity
Care Endpoints in Adults With Type 2 Diabetes: Screening and Therapeutic Targets at a Canadian Tertiary Diabetes Care Centre
Source : https://www.canadianjournalofdiabetes.com/article/S1499-2671(22)00211-8/fulltext
Although national diabetes guidelines recommend targets for various health parameters, studies have demonstrated a gap between recommendations and real-life practice. The objectives of the present study were to: 1) assess...
Conclusions: Patients with T2DM at the MUHC receive guideline-based measurements of health parameters more frequently than at other institutions. Achievement of target values was closer to that seen by Canadian specialists than by primary care. Although further analyses are necessary to help implement effective strategies for improvement,...
-
Dr Hamid3yrInteresting article, but further analyses are necessary to help implement effective strategies for improvement
-
Amy Gonzales, Physician3yrScreening and counseling are important in preventing diabetes.
Show More Comments
Aldehyde Dehydrogenase 2 Activator Augments the Beneficial Effects of Empagliflozin in Mice with Diabetes-Associated HFpEF - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36142350/
1 Division of Hypertension and Vascular Research, Department of Internal Medicine, Henry Ford Health System, Detroit, MI 48202, USA. 2 Department of Physiology, Wayne State University, Detroit, MI 48202, USA....
Conclusions: AMP-activated protein kinase (AMPK) pathways in ALDH2*2 mice with diabetes-associated HFpEF. This combination was even more effective than EMP alone. Our data indicate that ALDH2 activation along with the treatment of hypoglycemic agents may be a salient strategy to alleviate diabetes-associated HFpEF.